Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of ublituximab + TGR-1202 versus obinutuzumab + chlorambucil in chronic lymphocytic leukemia
MOH_2017-04-03_000297Phase 3Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ublituximab and umbralisib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (4 arms), sponsored by TG Therapeutics, Inc. Primary endpoint: Progression-free survival. Started Oct 2016; status: completed.
02
Drugs
ublituximabumbralisib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2017-04-03_000297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-03_000297.